Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APLNR | P35414 | 9/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | USP2 | O75604 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | BRCA1 | P38398 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4739113 | 0.91 | MDM2 (0.47) | APLNRKMT2AMEN1USP2MAPT | |
| SCHEMBL4740112 | 0.86 | APLNR (0.53) | APLNRKMT2AMEN1USP2MDM2 | |
| SCHEMBL4737525 | 0.83 | KMT2A (0.54) | APLNRKMT2AMEN1USP2MAPT | |
| SCHEMBL4739979 | 0.81 | MDM2 (0.45) | APLNRKMT2AMEN1MDM2ALDH1A1 | |
| SCHEMBL4739124 | 0.81 | HPGD (0.43) | APLNRKMT2AMEN1USP2MAPT | |
| SCHEMBL4740213 | 0.80 | KMT2A (0.42) | APLNRKMT2AMEN1USP2MAPT | |
| SCHEMBL4739974 | 0.79 | ALDH1A1 (0.38) | APLNRKMT2AMEN1USP2MAPT | |
| SCHEMBL17317042 | 0.79 | APLNR (0.51) | APLNRKMT2AMEN1USP2MAPT | |
| SCHEMBL4739136 | 0.78 | GAA (0.44) | KMT2AMEN1USP2MAPTKDM4E | |
| SCHEMBL4738618 | 0.78 | GAA (0.44) | KMT2AMEN1USP2MAPTKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2008089051-A1 | N-SUBSTITUTED GLYCINE DERIVATIVES: PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-07-24 | — | — | WO | disclosed |
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171756-A1 | N-Substituted Glycine Derivatives: Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN2, EGLN3 | APLNR 2034/4885KMT2A 734/4885MEN1 2935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.